Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 286596
Licensor grants to Licensee exclusive, perpetual, sub-licensable rights to Licensorâ€™s IP, Trade Marks (TM), and all technical knowhow to manufacture, distribute, market and commercialize the product in all countries outside the Territory if in any country outside the Territory that Licensor grants to Licensee and Licensee pays for any or all patent related costs or files for registration or files for regulatory approvals, CE certification, preclinical and clinical studies.
Licensor hereby appoints Licensee as an exclusive Distributor of the Product for the Territory in the Field of Use. As such, Licensee shall have the authority to purchase, market and sell the Product in the Territory in the Field of Use. Licensee may not Actively Promote Sales (e.g. through promotion, advertising, or by establishing branches or distribution depots) outside of the Territory. Furthermore, Licensee may only Actively Promote Product for the Field of Use. Licensee hereby accepts such appointment and agrees to use its best efforts to maximize sales of the Product in the Territory in the Field of Use. Licensee acknowledges that Licensees right to distribute is for the Territory in the Field of Use only.
DuraGraft â€“ Vascular Conduit Solution- For use in Cardiac and Peripheral Bypass Grafting with Arteries and Veins and For Vascular Surgeries. The product DuraGraft is a two-component system. Licensor will produce product component A and B either as bulk product or in separate containers ready for packaging to Licensee. Licensor will assist Licensee at Licenseeâ€™s cost, with technology transfer to allow Licensee to complete the manufacturing of the DuraGraft product at its ISO13485 certified site in the Territory or and release the product for commercial use in Licensee territories. Licensor will transfer all Intellectual Property and technologies to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.
A CE Marked Product â€“ Notified Body is BSI, Netherlands
Trademarks shall refer to any trademark used by Licensor in connection with the Product, whether derived from common law use, from registration or from statutory protection against unfair competition, including without limitation those rights to Licensorâ€™s corporate name, other trade names, model names and trademarks, including DURAGRAFT.
Intellectual Property and technologies are to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.
DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure.
IPSCIO Record ID: 27346
IPSCIO Record ID: 203364
Licensor transfers to Transferee all right, title and interest in and to all of the intellectual property, designs, ideas and concepts concerning the Project. Transferee understands and agrees that beyond the sketches and preliminary prototypes, there are no fixed assets associated with the Project.